Guidance
Serum Institute’s vaccine demonstrates significant efficacy against severe rotavirus gastroenteritis
Results from a Phase 3 efficacy study in India of the Serum Institute of India Pvt. Ltd.’s rotavirus vaccine BRVPV (known as ROTASIIL®) #were published in the journal Vaccine. The study showed the vaccine to be safe, well tolerated, and to provide significant efficacy against
severe rotavirus gastroenteritis. In 2013, an estimated 47,100 rotavirus deaths occurred in India, 22 percent of all rotavirus deaths that occurred globally. ROTASIIL reduced severe rotavirus diarrhea by more than a third – 39.5 percent over two years. Significantly, the vaccine efficacy was nearly 55 percent against the most severe and potentially life-threatening cases of rotavirus diarrhea, which represent the highest risk of dehydration, hospitalizations, and deaths. The results demonstrated by ROTASIIL in India appear generally comparable to the performance of RotaTeq® and Rotarix® in Bangladesh and in some African countries.
Authors
Languages
- English
Publication year
2017
Publisher
PATH
Type
Guidance
Categories
- Vaccines & delivery devices
Diseases
- Rotavirus
Tags
- New vaccine introduction
